Table 4.
Difference in biomarker concentrations in participants who had diseased activity, identified by the presence of GdE lesions, at the time of lumbar puncture, compared to those who did not present evidence of disease activity at the time of lumbar puncture.
| CSF biomarker | Disease activity at baseline | p-value | Detection method | |
|---|---|---|---|---|
| No (n = 49) | Yes (n = 31) | |||
| Median (25th, 75th quartile) | Median (25th, 75th quartile) | |||
| NfL (pg/mL) | 312 (193, 510) | 405.2 (228.4, 1160.1) | p = .073 | SIMOA |
| GFAP (pg/mL) | 2278 (771, 3264) | 1644 (871, 2317) | p = .175 | SIMOA |
| T-Tau (pg/mL) | 13 (4, 29) | 19 (7, 38) | p = .152 | SIMOA |
| UCHL-1 (pg/mL) | 443 (318, 640) | 399 (280, 612) | p = .542 | SIMOA |
| T-Tau (pg/mL) | 85 (60, 133) | 89 (69, 139) | p = .841 | CLEIA |
| P-Tau181 (pg/mL) | 14 (13, 22) | 13 (11, 17) | p = .084 | CLEIA |
| P-Tau181/T-Tau | 0.17 (0.15, 0.21) | 0.16 (0.10, 0.22) | p = .363 | CLEIA |
Note: GFAP: glial fibrillary acid protein; T-Tau: Total-Tau; UCHL-1: ubiquitin C-terminal hydrolase 1; P-Tau181: phosphor-Tau181.
Data are reported as either median (25th, 75th quartile).